Perspective on Initial Therapy Selection


Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.

Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Related Content